Aptose Biosciences Faces NASDAQ Delisting Notice

Ticker: APTOF · Form: 8-K · Filed: Apr 3, 2025 · CIK: 882361

Sentiment: bearish

Topics: delisting, listing-standards, sec-filing

Related Tickers: APTO

TL;DR

Aptose Biosciences got a NASDAQ delisting notice, effective March 31st. Big trouble ahead?

AI Summary

Aptose Biosciences Inc. filed an 8-K on April 3, 2025, reporting a notice of delisting or failure to meet continued listing standards with NASDAQ, effective March 31, 2025. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and headquartered in Toronto.

Why It Matters

This filing indicates potential delisting from NASDAQ, which could significantly impact the company's stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on a major exchange.

Key Players & Entities

FAQ

What specific continued listing rule or standard did Aptose Biosciences Inc. fail to satisfy?

The filing does not specify the exact rule or standard that Aptose Biosciences Inc. failed to satisfy, only that it received a notice of delisting or failure to meet such standards.

What is the effective date of the delisting notice?

The earliest event reported, which is the notice of delisting or failure to satisfy a continued listing rule or standard, was effective as of March 31, 2025.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on April 3, 2025.

What were Aptose Biosciences Inc.'s former names?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and prior to that, Imutec Pharma Inc.

Where is Aptose Biosciences Inc. incorporated and headquartered?

Aptose Biosciences Inc. is incorporated in Canada and its business address is in Toronto, Canada.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing